Abstract: The present invention relates to novel therapeutic or prophylactic treatment in human subjects. The present invention results in part from the discovery that antagonists of IL-18R? are effective in vivo for treating diseases. Accordingly, the invention provides a method of treating, preventing or ameliorating the symptoms of an autoimmune or demyelinating disease (such as multiple sclerosis) in a subject, preferably a human subject, said method comprising administering to the subject a therapeutically effective amount of an antagonist of IL-18R?. The invention also pertains to the use of an antagonist of IL-18R? in the manufacture of a medicament for the treatment of an autoimmune or demyelinating diseases (such as multiple sclerosis).
Abstract: The present invention relates to the gene, Nogo, its encoded protein products, as well as derivatives and analogs thereof. Production of Nogo proteins, derivatives, and antibodies is also provided. The invention further relates to therapeutic compositions and methods of diagnosis and therapy.
Abstract: The present invention relates to collections of repeat proteins comprising repeat modules which are derived from one or more repeat units of a family of naturally occurring repeat proteins, to collections of nucleic acid molecules encoding said repeat proteins, to methods for the constructions and application of such collections and to individual members of such collections.
Type:
Grant
Filed:
September 10, 2001
Date of Patent:
August 26, 2008
Assignee:
University of Zurich
Inventors:
Michael Tobias Stumpp, Patrick Forrer, Hans Kaspar Binz, Andreas Plückthun
Abstract: The present invention relates to novel mutants of bone morphogenetic proteins (BMPs) useful as inhibitors of heterotopic ossification. Specifically, the present invention related to novel mutants containing only the entire region involved in the formation of finger 2 including the wrist epitope of a BMP with a specific cysteine residue or specific cysteine residues replaced by a different amino acid. The present invention also relates to pharmaceutical compositions containing these mutants and to methods for using the mutants and pharmaceutical compositions in therapy.
Abstract: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.
Abstract: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
Type:
Grant
Filed:
December 30, 2004
Date of Patent:
March 11, 2008
Assignee:
University of Zurich
Inventors:
Andreas Pluckthun, Annemarie Honegger, Joerg Willuda
Abstract: A composition for coating comprising at least one compound of formula (I): R<a>Si(R<1>)n(X<1>)3-n, and optionally at least one compound of formula (II): R<b>Si(R<2>)m(X<2>)3-m, wherein R<a> is a straight-chain or branched C(1-24) alkyl group, R<b> is an aromatic group, such as an optionally substituted carbocyclic and heterocyclic group comprising five-, six- or ten-membered ring systems, which is linked by a single covalent bond or a spacer unit, such as a straight-chain or branched alkyl residue having 1 to 8 carbon atoms, to the Si- atom, R<1> and R<2> are, independently of each other a lower alkyl group, such as a straight chain and branched hydrocarbon radical having 1 to 6 carbon atoms, X<1> and X<2> are independently of each other a hydrolysable group, such as a halogen or an alkoxy group and n, m are independently of each other 0 or 1, with the proviso that if n and m are independently of each other 0 or 1, X may represent the sam
Type:
Application
Filed:
June 23, 2004
Publication date:
November 15, 2007
Applicant:
UNIVERSITY OF ZURICH
Inventors:
Jan Zimmermann, Stefan Seeger, Georg Artus, Stefan Jung
Abstract: A light-emitting textile structure, which in particular is useful for medical purposes, comprises a flat support (2) and a plurality of light-emitting elements (4) fixed thereto. Each light-emitting element comprises a light-supplying optical fiber (6), to each optical fiber (6) there being associated exactly one light-emitting element (4), which comprises at least one output zone formed by a local curvature of the optical fiber. The local curvature is selected in such a way that a lateral exit of light from the optical fiber occurs due to the absence of total reflection.
Type:
Grant
Filed:
May 11, 2005
Date of Patent:
September 25, 2007
Assignee:
University of Zurich EMPA
Inventors:
Heinrich Walt, Bärbel Selm, Thomas Wessel
Abstract: The present invention relates to novel mutants of bone morphogenetic proteins (BMPs) useful as inhibitors of heterotopic ossification. Specifically, the present invention relates to novel mutants containing only the entire region involved in the formation of finger 2 including the wrist epitope of a BMP with a specific cysteine residue or specific cysteine residues replaced by a different amino acid. The present invention also relates pharmaceutical compositions containing these mutants and to the use of the mutants and pharmaceutical compositions in therapy.
Abstract: The present invention relates to pharmaceutical compositions containing at least one bone morphogenetic protein (BMP) and a plasticizer in a pharmaceutically acceptable carrier, such as in a biodegradable polymer, in amounts providing a synergistic bone forming and bone healing effect. The present invention further relates to methods of treating orthopedic and dental, including periodontal, diseases by simultaneously administering to a subject in a need of such treatment at least one bone morphogenetic protein (BMP) and at least one plasticizer optionally in a pharmaceutically acceptable carrier, in amounts providing a synergistic bone forming effect.
Abstract: Novel polymer compositions that are useful in the manufacture of medical implants, implants having osteogenic properties and methods of making the implants are disclosed. Polymer compositions include a base material having a polymer matrix of resorbable polymer(s) or copolymer(s), and a glycerol mono-, di-, or triester derivative, wherein the glycerol mono-, di-, or triester derivative is present in an amount imparting osteogenic properties for the composition.
Abstract: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
Type:
Application
Filed:
December 30, 2004
Publication date:
July 20, 2006
Applicant:
University of Zurich
Inventors:
Andreas Pluckthun, Annemarie Honegger, Jorg Willuda
Abstract: The present invention relates to pharmaceutical compositions containing a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier, such as a biodegradable polymer. The present invention further relates to methods of treating orthopaedic and dental, including periodontal, diseases by simultaneously administering a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier to patients in need of such treatment.
Abstract: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.
Abstract: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.
Abstract: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
Type:
Grant
Filed:
October 4, 2001
Date of Patent:
April 25, 2006
Assignee:
University of Zurich
Inventors:
Andreas Plückthun, Annemarie Honegger, Jörg Willuda
Abstract: The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include metalloproteases associated with glioblastoma cells. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system.
Type:
Grant
Filed:
October 1, 1997
Date of Patent:
November 1, 2005
Assignee:
University of Zurich
Inventors:
Martin E. Schwab, Pierenrico W. Caroni, Paolo A. Paganetti
Abstract: Template-fixed ?-hairpin loop mimetics comprising a template corresponding to one of the structures (a), (b), (c), (d), (e), (f), (g), (h) and a template-fixed chain of 4 to 20 ?-amino acid residues which, if their ?-C atom is asymmetric, have L-configuration can be manufactured by a novel process which is based on a mixed solid- and solution phase synthetic strategy. If desired, this process can be modified to give the enantiomers of these template-fixed ?-hairpin loop mimetics. These enantiomers are novel compounds, and many of said template-fixed ?-hairpin loop mimetics themselves are also novel compounds. The template-fixed ?-hairpin loop mimetics and their enantiomers can mimick flat surfaces of proteins and thus be used to probe large surface protein-protein interactions. Accordingly they can serve as lead finding tools for protein targets where it is difficult to find small-molecular-weight lead compounds.
Abstract: The present invention relates to the modification of immunoglobulin superfamily (IgSF) domains, IgSF fragments and fusion proteins thereof, especially to the modification of antibody derivatives, so as to improve their solubility, and hence the yield, and ease of handling. The inventors have found that this can be achieved by making the region which comprised the interface with domains adjoined to said IgSF domain in a larger fragment or a full IgSF protein, and which becomes exposed in the IgSF domain, more hydrophilic by modification. The present invention describes DNA sequences encoding modified IgSF domains or fragments and fusion proteins thereof, vectors and hosts containing these DNA sequences, IgSF domains or fragments or fusion proteins obtainable by expressing said DNA sequences in suitable expression systems, and a method for modifying IgSF domains, so as to improve their solubility, expressibility and ease of handling.
Type:
Grant
Filed:
January 15, 1999
Date of Patent:
November 9, 2004
Assignee:
University of Zurich
Inventors:
Andreas Plückthun, Lars Nieba, Annemarie Honegger
Abstract: The present invention relates to fatty acid 13-hydroperoxide lyase protein from guava (Psidium guajava) and the gene encoding the protein. Expression systems for recombinant guava 13-hydroperoxide lyase and methods of using recombinant guava 13-hydroperoxide lyase for the production of green notes are provided.
Type:
Grant
Filed:
January 9, 2002
Date of Patent:
August 24, 2004
Assignees:
Firmenich SA, Vanderbilt University, The University of Zurich
Inventors:
Ian Michael Whitehead, Alan John Slusarenko, Urs Wäspi, Duncan James Horatio Gaskin, Alan Richard Brash, Nathalie Tijet